Emergency use authorization adds a new dimension to Simparica Trio

Zoetis (ZTS) is back in focus after the U.S. Food and Drug Administration granted Emergency Use Authorization for Simparica Trio to treat New World screwworm infestations in dogs and puppies.

This emergency clearance applies to myiasis caused by Cochliomyia hominivorax larvae, a condition that can severely damage animal tissue if untreated. It comes in addition to Simparica Trio’s existing approvals for broad parasite protection in companion animals.

Zoetis shares have slipped over recent months, with a 30 day share price return of 3.62% and a year to date share price return down 41.4%, while the 1 year total shareholder return is down 51.2%. This points to fading momentum despite product updates, the recent guidance cut, and finance leadership changes.

If developments around Simparica Trio have you reassessing animal health exposure, it can also be useful to see what is happening in other healthcare related areas, including companies using AI in medicine through the 42 healthcare AI stocks

Zoetis now trades well below both its recent levels and the average analyst target, with a wide gap between price and fair value estimates. The key issue is where in that range you think fair value really sits.

Most popular Zoetis narrative: 21% undervalued

According to the most widely followed Zoetis narrative, a fair value of $92.92 sits well above the recent $73.79 close. That gap is what this valuation debate turns on.

On one hand it is not a business that is going to grow much; on the other hand, it is also not likely to collapse catastrophically. It is a double-edged sword. The company cites generics as a potential risk in its financial statements. I am not sure how much of this could be attributable to the 11% year-over-year decline in Pet segment revenues, but this is something to watch out for if you are interested in investing in the business.

Want to see how a low growth profile still supports a higher fair value tag? According to ValueInvestingSubstack, the valuation focuses on earnings resilience, generous margins and where the market eventually sets the P/E multiple.

Result: Fair Value of $92.92 (UNDERVALUED)

However, Zoetis still carries clear risks, including generic competition and any prolonged weakness in US Companion Animal revenues that could challenge this undervalued narrative.

Next Steps

If the mixed signals on Zoetis leave you unsure, now is a good time to review the full picture for yourself and decide where you stand. Take a closer look at the balance of 4 key rewards and 1 important warning sign

Looking for more Zoetis investment ideas?

If Zoetis has you rethinking your watchlist, this is the moment to widen your search and stress test your next moves with fresh ideas.

• Spot potential bargains early by reviewing companies highlighted in the 52 high quality undervalued stocks before the crowd focuses on them.
• Prioritize financial resilience by scanning stocks in the solid balance sheet and fundamentals stocks screener (51 results) so you are not caught off guard by weak balance sheets.
• Hunt for off-the-radar opportunities by checking the screener containing 20 high quality undiscovered gems that most investors are not watching yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.